查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598801

子宮癌治療和診斷市場：按癌症類型和產品分類 - 2025-2030 年全球預測

Uterine Cancer Therapeutics & Diagnostics Market by Cancer Type (Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma), Product (Diagnostics, Therapeutics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年子宮癌藥物和診斷市場價值為225.5億美元，預計2024年將達到239.5億美元，複合年成長率為6.29%，到2030年將達到34.5億美元，預計將達到9000萬美元。

子宮癌治療和診斷市場的範圍包括子宮癌治療和診斷的醫療產品和服務的開發、測試和分銷。這包括藥物、手術治療、放射治療、診斷測試和影像工具。由於人口老化、生活方式的改變以及早期診斷意識的增強等因素，子宮內膜癌的盛行率不斷增加，因此對這個市場的需求產生了。應用範圍從醫院和癌症治療中心等專業醫療機構到專注於腫瘤研究的研究機構。一系列最終用途包括醫療保健提供者、診斷實驗室、專注於女性健康的製藥公司等。

主要市場統計
基準年[2023] 225.5億美元
預測年份 [2024] 239.5億美元
預測年份 [2030] 345.9億美元
複合年成長率（%） 6.29%

關鍵的成長要素包括標靶治療、個人化醫療和非侵入性診斷技術的進步。最新的潛在機會在於人工智慧成像、分子診斷的增強以及免疫療法和荷爾蒙療法治療產品平臺的擴展。解決獲得醫療保健的地區差異和整合遠距遠端醫療服務代表著巨大的商機。然而，市場開拓面臨的挑戰包括高昂的藥物開發成本、嚴格的法律規範以及低收入地區的財政限制，這些都阻礙了最先進治療的廣泛採用。

該領域的研究和開發可以集中於開發具有成本效益的篩檢工具並推進遺傳和生物標記研究，以更好地了解個別患者概況。還有希望研究微創手術技術和以患者為中心的癌症治療方法，以最大限度地提高治療後的生活品質。市場動態洞察表明，市場本質上是動態的，對改善治療結果和以患者為中心的解決方案的需求推動了對生物技術和製藥公司之間的創新和合作的強烈關注。總體而言，利用尖端研究、戰略夥伴關係關係以及對患者負擔和可及性的關注將決定該市場的業務成長。

市場動態：快速發展的子宮癌藥物和診斷市場的關鍵市場洞察

由於供需之間的動態相互作用，子宮癌治療和診斷市場正在經歷轉型。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 提高醫生和醫療保健提供者對子宮內膜癌的認知
    • 女性健康日益重要
    • 醫療保健支出不斷增加，政府對提供適當的醫療保健解決方案的興趣日益濃厚
  • 市場限制因素
    • 治療方法昂貴、副作用大、藥物毒性嚴重
  • 市場機會
    • 癌症篩檢和治療方法的進步
    • 發展中國家正在針對子宮內膜癌的嚴重性和重要性組織各種計畫。
  • 市場挑戰
    • 抗癌藥物臨床試驗成功率低

波特五力：駕馭子宮癌藥物和診斷藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解子宮癌治療和診斷藥物市場的外部影響

外部宏觀環境因素在塑造子宮癌治療和診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解子宮癌治療和診斷藥物市場的競爭狀況

子宮癌治療和診斷市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

子宮癌治療與診斷市場供應商的 FPNV 定位矩陣績效評估

FPNV定位矩陣是評估子宮癌治療和診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，描繪子宮癌治療和診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，子宮癌治療和診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高醫師和醫護人員對子宮癌的認知
      • 女性健康日益重要
      • 醫療保健成本不斷上升，政府越來越注重提供適當的醫療保健解決方案
    • 抑制因素
      • 治療方法昂貴、副作用大、藥物毒性嚴重
    • 機會
      • 癌症檢測和治療方法的進展
      • 新興國家針對子宮癌的嚴重性和重要性實施了各種計劃
    • 任務
      • 癌症藥物臨床試驗的成功率較低。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按癌症類型分類的子宮癌治療和診斷藥物市場

  • 腺鱗癌
  • 子宮內膜腺癌
  • 乳頭狀漿液性癌
  • 子宮肉瘤

第7章子宮癌治療與診斷藥物市場：依產品

  • 診斷
    • 切片檢查
    • 電腦斷層掃描
    • 子宮頸擴張及刮除術
    • 子宮鏡檢查
    • 骨盆腔超音波檢查
  • 治療藥物
    • 化療
    • 免疫療法
    • 放射治療
    • 外科手術

第8章北美和南美子宮癌治療和診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區子宮癌治療與診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲子宮癌治療和診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Ability Pharma
  • AstraZeneca PLC
  • BioMerieux SA
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-4342CA32670E

The Uterine Cancer Therapeutics & Diagnostics Market was valued at USD 22.55 billion in 2023, expected to reach USD 23.95 billion in 2024, and is projected to grow at a CAGR of 6.29%, to USD 34.59 billion by 2030.

The scope of the uterine cancer therapeutics and diagnostics market encompasses the development, testing, and distribution of medical products and services aimed at treating and diagnosing uterine cancer. This includes pharmaceuticals, surgical treatments, radiation therapies, diagnostic tests, and imaging tools. The necessity of this market arises from the increasing incidence rate of uterine cancer, driven by factors such as an aging population, lifestyle changes, and rising awareness about early diagnosis. The application scope extends from professional healthcare establishments like hospitals and cancer treatment centers to research institutions focused on oncological studies. The end-use scope highlights inclusion across healthcare providers, diagnostic labs, and pharmaceutical companies focusing on women's health.

KEY MARKET STATISTICS
Base Year [2023] USD 22.55 billion
Estimated Year [2024] USD 23.95 billion
Forecast Year [2030] USD 34.59 billion
CAGR (%) 6.29%

Key growth influences include advancements in targeted therapies, personalized medicine, and non-invasive diagnostic technologies. The latest potential opportunities lie in leveraging artificial intelligence for diagnostic imaging, enhancing molecular diagnostics, and expanding therapeutic product pipelines with immunotherapies and hormonal treatments. Addressing regional disparities in healthcare access and integrating telehealth services present substantive opportunities. However, market growth is challenged by high costs of drug development, stringent regulatory frameworks, and financial constraints in low-income regions, which hinder wide-scale adoption of cutting-edge treatments.

Innovation in this sector can focus on developing cost-effective screening tools and making advances in genetic and biomarker research to understand individual patient profiles better. There's promise in researching minimally invasive surgical techniques and patient-centric cancer treatment regimens that maximize quality of life post-treatment. Insight into market nature suggests it is dynamic, with a strong focus on innovation and collaboration across biotech and pharmaceutical firms, driven by a need for improved treatment outcomes and patient-centric solutions. Overall, capitalizing on cutting-edge research, strategic partnerships, and focusing on patient affordability and accessibility will define business growth in this market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Uterine Cancer Therapeutics & Diagnostics Market

The Uterine Cancer Therapeutics & Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness of uterine cancer in physicians and healthcare providers
    • Rising in importance of the women health
    • Increasing healthcare expenditure and rising focus of government on providing adequate healthcare solutions
  • Market Restraints
    • Expensive treatment methods along with adverse side effects and severe toxicity of the medications
  • Market Opportunities
    • Increasing advancements in the cancer screening and treatment methods
    • Developing countries organising various programmes about uterine cancer severity and importance
  • Market Challenges
    • Low success rate of cancer drug clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the Uterine Cancer Therapeutics & Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Uterine Cancer Therapeutics & Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Uterine Cancer Therapeutics & Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Uterine Cancer Therapeutics & Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Uterine Cancer Therapeutics & Diagnostics Market

A detailed market share analysis in the Uterine Cancer Therapeutics & Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Uterine Cancer Therapeutics & Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Uterine Cancer Therapeutics & Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Uterine Cancer Therapeutics & Diagnostics Market

A strategic analysis of the Uterine Cancer Therapeutics & Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Uterine Cancer Therapeutics & Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ability Pharma, AstraZeneca PLC, BioMerieux S.A., Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Uterine Cancer Therapeutics & Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma.
  • Based on Product, market is studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Biopsy, CT Scan, Dilation & Curettage, Hysteroscopy, and Pelvic Ultrasound. The Therapeutics is further studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Surgery.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness of uterine cancer in physicians and healthcare providers
      • 5.1.1.2. Rising in importance of the women health
      • 5.1.1.3. Increasing healthcare expenditure and rising focus of government on providing adequate healthcare solutions
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive treatment methods along with adverse side effects and severe toxicity of the medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing advancements in the cancer screening and treatment methods
      • 5.1.3.2. Developing countries organising various programmes about uterine cancer severity and importance
    • 5.1.4. Challenges
      • 5.1.4.1. Low success rate of cancer drug clinical trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Uterine Cancer Therapeutics & Diagnostics Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Adenosquamous Carcinoma
  • 6.3. Endometrial Adenocarcinoma
  • 6.4. Papillary Serous Carcinoma
  • 6.5. Uterine Sarcoma

7. Uterine Cancer Therapeutics & Diagnostics Market, by Product

  • 7.1. Introduction
  • 7.2. Diagnostics
    • 7.2.1. Biopsy
    • 7.2.2. CT Scan
    • 7.2.3. Dilation & Curettage
    • 7.2.4. Hysteroscopy
    • 7.2.5. Pelvic Ultrasound
  • 7.3. Therapeutics
    • 7.3.1. Chemotherapy
    • 7.3.2. Immunotherapy
    • 7.3.3. Radiation Therapy
    • 7.3.4. Surgery

8. Americas Uterine Cancer Therapeutics & Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Ability Pharma
  • 4. AstraZeneca PLC
  • 5. BioMerieux S.A.
  • 6. Danaher Corporation
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Siemens Healthineers AG
  • 15. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ADENOSQUAMOUS CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY ENDOMETRIAL ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PAPILLARY SEROUS CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY UTERINE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DILATION & CURETTAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PELVIC ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023